WallStSmart

CareCloud, Inc. (CCLD)vsEli Lilly and Company (LLY)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Eli Lilly and Company generates 61829% more annual revenue ($79.67B vs $128.64M). LLY leads profitability with a 33.5% profit margin vs 6.2%. CCLD appears more attractively valued with a PEG of 0.31. LLY earns a higher WallStSmart Score of 76/100 (B+).

CCLD

Buy

51

out of 100

Grade: C-

Growth: 4.0Profit: 6.0Value: 8.7Quality: 4.5
Piotroski: 3/9Altman Z: 2.20

LLY

Strong Buy

76

out of 100

Grade: B+

Growth: 9.3Profit: 10.0Value: 5.0Quality: 6.0
Piotroski: 6/9Altman Z: 2.06
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

CCLDUndervalued (+65.8%)

Margin of Safety

+65.8%

Fair Value

$6.55

Current Price

$2.05

$4.50 discount

UndervaluedFair: $6.55Overvalued

Intrinsic value data unavailable for LLY.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

CCLD2 strengths · Avg: 9.0/10
PEG RatioValuation
0.3110/10

Growing faster than its price suggests

Revenue GrowthGrowth
16.4%8/10

16.4% revenue growth

LLY6 strengths · Avg: 9.7/10
Market CapQuality
$994.92B10/10

Mega-cap, among the largest globally

Return on EquityProfitability
78.8%10/10

Every $100 of equity generates 79 in profit

Profit MarginProfitability
33.5%10/10

Keeps 34 of every $100 in revenue as profit

Operating MarginProfitability
54.2%10/10

Strong operational efficiency at 54.2%

Revenue GrowthGrowth
47.7%10/10

Revenue surging 47.7% year-over-year

EPS GrowthGrowth
26.2%8/10

Earnings expanding 26.2% YoY

Areas to Watch

CCLD4 concerns · Avg: 3.3/10
P/E RatioValuation
29.3x4/10

Moderate valuation

Market CapQuality
$87.11M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
6.2%3/10

6.2% margin — thin

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

LLY3 concerns · Avg: 3.0/10
P/E RatioValuation
37.7x4/10

Premium valuation, high expectations priced in

Debt/EquityHealth
1.623/10

Elevated debt levels

Price/BookValuation
29.4x2/10

Trading at 29.4x book value

Comparative Analysis Report

WallStSmart Research

Bull Case : CCLD

The strongest argument for CCLD centers on PEG Ratio, Revenue Growth. Revenue growth of 16.4% demonstrates continued momentum. PEG of 0.31 suggests the stock is reasonably priced for its growth.

Bull Case : LLY

The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 33.5% and operating margin at 54.2%. Revenue growth of 47.7% demonstrates continued momentum.

Bear Case : CCLD

The primary concerns for CCLD are P/E Ratio, Market Cap, Profit Margin. Debt-to-equity of 3.10 is elevated, increasing financial risk.

Bear Case : LLY

The primary concerns for LLY are P/E Ratio, Debt/Equity, Price/Book. Debt-to-equity of 1.62 is elevated, increasing financial risk.

Key Dynamics to Monitor

CCLD carries more volatility with a beta of 1.50 — expect wider price swings.

LLY is growing revenue faster at 47.7% — sustainability is the question.

LLY generates stronger free cash flow (7.8B), providing more financial flexibility.

Monitor HEALTH INFORMATION SERVICES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

LLY scores higher overall (76/100 vs 51/100), backed by strong 33.5% margins and 47.7% revenue growth. CCLD offers better value entry with a 65.8% margin of safety. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

CareCloud, Inc.

HEALTHCARE · HEALTH INFORMATION SERVICES · USA

CareCloud, Inc., a healthcare information technology (IT) company, provides a suite of cloud-based solutions and related business services to healthcare providers and hospitals primarily in the United States. The company is headquartered in Somerset, New Jersey.

Visit Website →

Eli Lilly and Company

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.

Visit Website →

Want to dig deeper into these stocks?